PaxMedica Inc (PK:PXMD)
Business Focus: Biotechnology & Medical Research
May 15, 2024 08:30 am ET
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
via IBN -- PaxMedica, Inc. (the “Company” or “PaxMedica”) (OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced it has timely filed a formal notice of appeal with the Nasdaq Office of...
May 07, 2024 08:30 am ET
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not...
Apr 26, 2024 08:30 am ET
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast
via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to...
Apr 23, 2024 08:30 am ET
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request for IV suramin from the...
Apr 16, 2024 04:30 pm ET
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
via IBN -- PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency...
Apr 11, 2024 04:30 pm ET
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal registration/validation batches of PAX-101, an IV...
Mar 13, 2024 08:20 am ET
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. This comprehensive overview showcases PaxMedica’s...
Dec 06, 2023 08:00 am ET
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman
TARRYTOWN, NY / ACCESSWIRE / December 6, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the release of a Fireside Chat video featuring Howard Weisman, Chairman and CEO.
Nov 22, 2023 04:10 pm ET
PaxMedica Announces Closing of $7.0 Million Public Offering
TARRYTOWN, NY / ACCESSWIRE / November 22, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the closing of its previously announced public offering of an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock, at a public offering price of $1.30 per share (or common stock equivalent in lieu thereof) and accompanying warrant. The warr
Nov 20, 2023 09:15 am ET
PaxMedica Announces Pricing of $7.0 Million Public Offering
TARRYTOWN, NY / ACCESSWIRE / November 20, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the pricing of its public offering of an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock, at a combined public offering price of $1.30 per share (or common stock equivalent in lieu thereof) and a
Nov 17, 2023 08:00 am ET
PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data
via IBN –PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers...
Nov 15, 2023 06:50 pm ET
PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update
TARRYTOWN, NY / ACCESSWIRE / November 15, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced today a comprehensive business update along with its financial results for the third quarter ended September 30, 2023.
Nov 09, 2023 08:00 am ET
PaxMedica's Chief Medical Officer Discusses FDA Meeting Highlights on The Bell2Bell Podcast
IBN, a leading communications organization focused on linking public companies to the investment community, has unveiled the latest episode of The Bell2Bell Podcast, featuring an exclusive interview with David Hough, Chief Medical Officer at...
Nov 08, 2023 08:31 am ET
Thinking about buying stock in PaxMedica, Applied Therapeutics, Tharimmune, Singular Genomics Systems, or BIOLASE?
NEW YORK, Nov. 8, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PXMD, APLT, THAR, OMIC, and BIOL.
Nov 08, 2023 08:31 am ET
Thinking about buying stock in Ventyx Biosciences, Senti Biosciences, PaxMedica, AGNC Investment, or Lumos Pharma?
NEW YORK, Nov. 8, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTYX, SNTI, PXMD, AGNC, and LUMO.
Nov 07, 2023 08:00 am ET
PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal
TARRYTOWN, NY / ACCESSWIRE / November 7, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the publication of research findings in the Annals of General Psychiatry. The research, led by Chief Medical Officer Dr. David Hough, along with a team of renowned co-authors specializing in Autism Spectrum Disorder (ASD), the research explores the potential of low-dose suramin intr
Nov 02, 2023 08:30 am ET
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)
via IBN -- PaxMedica, Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, has engaged Bourne Partners, a leading financial services firm specializing in the pharma, pharma services,...
Oct 31, 2023 08:00 am ET
PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
via IBN -- PaxMedica, Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, announced today the successful acquisition of certain suramin research assets from Rediscovery...
Oct 30, 2023 11:30 am ET
PaxMedica Announces 1-for-17 Reverse Stock Split
via IBN — PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with...
Oct 27, 2023 09:31 am ET
Thinking about buying stock in Nextplay Technologies, ABVC Biopharma, PaxMedica, Mustang Bio, or NXU Inc.?
NEW YORK, Oct. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NXTP, ABVC, PXMD, MBIO, and NXU.
Oct 26, 2023 01:51 pm ET
PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication
via IBN -- PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General Psychiatry, an internationally recognized scientific psychiatry publication, has accepted the manuscript titled...
Oct 26, 2023 08:00 am ET
PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data
TARRYTOWN, NY / ACCESSWIRE / October 26, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a clinical-stage biopharmaceutical company, announced the completion of a type-B meeting with the FDA. During the live meeting, the company discussed the positive results of the recent data from its PAX-HAT-301 study of suramin in Stage One Human African Sleeping Sickness caused by Trypanosoma brucei rhodesiense, a rare and fatal parasitic disease if left untreated.
Oct 18, 2023 10:10 am ET
The Bell2Bell Podcast featuring Howard Weisman, CEO and Buzz Woods of PaxMedica, Inc. (Nasdaq: PXMD)
via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to...
Oct 10, 2023 08:00 am ET
PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023
TARRYTOWN, NY / ACCESSWIRE / October 10, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced its Gold Sponsorship of The BRAIN Foundation's esteemed Synchrony Symposia 2023.
Aug 30, 2023 08:00 am ET
PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference
via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious...
Aug 16, 2023 08:30 am ET
PaxMedica Appoints David Hough M.D. as Chief Medical Officer
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions...
Aug 09, 2023 04:15 pm ET
PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today...
Aug 08, 2023 09:00 am ET
PaxMedica to Join Fireside Chat with PCG Advisory Following Positive Top Line Results from PAX-HAT-301 Study
PaxMedica to discuss significance of Phase 3 study results
Jul 24, 2023 08:00 am ET
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious...
Jul 06, 2023 08:00 am ET
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD) and Vox Nova LLC (VoxNova), a privately held corporation, today announced that they have signed an exclusive pharmacy distribution agreement for PaxMedica’s lead pipeline asset, PAX-101. PaxMedica...
Jun 22, 2023 08:30 am ET
PaxMedica Comments on Common Stock Volatility
via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious...
Jun 20, 2023 08:30 am ET
PaxMedica CEO Interviewed by The BRAIN Foundation
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions...
Jun 14, 2023 08:00 am ET
PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions...
Jun 08, 2023 08:00 am ET
PaxMedica Enters Research Collaboration Agreement With PoloMar Health for Phase II Study in Autism Spectrum Disorder
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions...
Jun 01, 2023 08:00 am ET
PaxMedica Completes HAT-301 Registrational Trial for PAX-101
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD), and other serious...
May 15, 2023 04:13 pm ET
PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today...
Apr 19, 2023 08:30 am ET
PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today...
Mar 29, 2023 07:21 pm ET
PaxMedica, Inc. Provides Business Update and Reports Fourth Quarter 2022 Financial Results
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today...
Mar 20, 2023 08:00 am ET
PaxMedica Holds Meeting of Scientific Advisory Board
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today...
Feb 15, 2023 07:30 am ET
PaxMedica Releases 2022 Shareholder Letter
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today...
Feb 03, 2023 08:00 am ET
PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today...
Jan 20, 2023 01:31 pm ET
PaxMedica to Present at the Jan 26th Virtual Investor Summit Microcap Event
via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today...
Dec 14, 2022 08:00 am ET
PaxMedica, Inc. Launches Updated Corporate Website at PaxMedica.com
via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today...
Nov 22, 2022 08:00 am ET
PaxMedica to Present at the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today...
Nov 17, 2022 08:29 pm ET
PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today...
Nov 15, 2022 08:00 am ET
PaxMedica, Inc. Provides Business Update and Reports Third Quarter 2022 Financial Results
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today...
Nov 08, 2022 08:00 am ET
PaxMedica Initiates Clinical Program to Advance PAX-101 Towards FDA Submission
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms, today announced that it...
Oct 24, 2022 08:00 am ET
PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical-stage biopharmaceutical company focused on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms such as autism...
Oct 03, 2022 08:00 am ET
PaxMedica Appoints Specialty Pharma Industry Leader Charles J. Casamento to Its Board of Directors
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical-stage biopharmaceutical company focused on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms such as autism...
Aug 26, 2022 09:50 am ET
Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc.
Shares will Trade on Nasdaq Capital Market under Ticker Symbol "PXMD"
Aug 26, 2022 08:00 am ET
PaxMedica, Inc. Announces Pricing of Initial Public Offering
via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms, today announced the...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.